Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 674

1.

Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer.

Kim TW, Peeters M, Thomas AL, Gibbs P, Hool K, Zhang J, Ang A, Bach BA, Price T.

Clin Cancer Res. 2018 Jun 13. pii: clincanres.3377.2017. doi: 10.1158/1078-0432.CCR-17-3377. [Epub ahead of print]

PMID:
29898991
2.

MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors.

Sakthianandeswaren A, Parsons M, Mouradov D, MacKinnon RN, Catimel B, Liu S, Palmieri M, Love CG, Jorissen RN, Li S, Whitehead L, Putoczki TL, Preaudet A, Tsui C, Nowell CJ, Ward RL, Hawkins NJ, Desai J, Gibbs P, Ernst M, Street I, Buchert M, Sieber OM.

Cancer Discov. 2018 Jun 7. pii: CD-17-0909. doi: 10.1158/2159-8290.CD-17-0909. [Epub ahead of print]

PMID:
29880585
3.

Treatment of Sarcoma Lung Metastases with Stereotactic Body Radiotherapy.

Lindsay AD, Haupt EE, Chan CM, Spiguel AR, Scarborough MT, Zlotecki RA, Gibbs PC.

Sarcoma. 2018 Apr 1;2018:9132359. doi: 10.1155/2018/9132359. eCollection 2018.

4.

Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis.

Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M.

Expert Rev Anticancer Ther. 2018 Apr;18(4):339-349. doi: 10.1080/14737140.2018.1444481. Epub 2018 Mar 1.

PMID:
29478352
5.

Outcomes of renal transplant from donors with polycystic kidney disease.

Shamali A, Milsom-Mcquillan S, Gibbs P.

Int J Surg. 2018 Mar;51:229-232. doi: 10.1016/j.ijsu.2018.01.049. Epub 2018 Feb 7. Review.

PMID:
29425828
6.

Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.

Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K, Elsaleh H, Kosmider S, Wong R, Yip D, Lee M, Tran B, Rangiah D, Burge M, Goldstein D, Singh M, Skinner I, Faragher I, Croxford M, Bampton C, Haydon A, Jones IT, S Karapetis C, Price T, Schaefer MJ, Ptak J, Dobbyn L, Silliman N, Kinde I, Tomasetti C, Papadopoulos N, Kinzler K, Volgestein B, Gibbs P.

Gut. 2018 Feb 2. pii: gutjnl-2017-315852. doi: 10.1136/gutjnl-2017-315852. [Epub ahead of print]

PMID:
29420226
7.

Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.

Williams DS, Mouradov D, Jorissen RN, Newman MR, Amini E, Nickless DK, Teague JA, Fang CG, Palmieri M, Parsons MJ, Sakthianandeswaren A, Li S, Ward RL, Hawkins NJ, Faragher I, Jones IT, Gibbs P, Sieber OM.

Gut. 2018 Jan 30. pii: gutjnl-2017-315664. doi: 10.1136/gutjnl-2017-315664. [Epub ahead of print]

PMID:
29382774
8.

Detection and localization of surgically resectable cancers with a multi-analyte blood test.

Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Dal Molin M, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Vogelstein JT, Browne JD, Schoen RE, Brand RE, Tie J, Gibbs P, Wong HL, Mansfield AS, Jen J, Hanash SM, Falconi M, Allen PJ, Zhou S, Bettegowda C, Diaz LA Jr, Tomasetti C, Kinzler KW, Vogelstein B, Lennon AM, Papadopoulos N.

Science. 2018 Feb 23;359(6378):926-930. doi: 10.1126/science.aar3247. Epub 2018 Jan 18.

PMID:
29348365
9.

Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.

Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, Wasan H, Fakih M, Gibbs P, Knuth A, Sangro B, Soulen MC, Pittari G, Sharma RA.

J Gastrointest Oncol. 2017 Dec;8(6):1079-1099. doi: 10.21037/jgo.2017.09.10. Review.

10.

Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers.

Lee B, Hutchinson R, Wong HL, Tie J, Putoczki T, Tran B, Gibbs P, Christie M.

Semin Cancer Biol. 2017 Dec 16. pii: S1044-579X(17)30123-2. doi: 10.1016/j.semcancer.2017.12.009. [Epub ahead of print] Review.

PMID:
29258858
11.

Adequate SIRT activity dose is as important as adequate chemotherapy dose - Authors' reply.

Sharma RA, Gibbs P, Sharma NK, Ricke J, Taieb J, Moschandreas J, Virdee PS, Dutton P, van Hazel G, Wasan HS.

Lancet Oncol. 2017 Nov;18(11):e637. doi: 10.1016/S1470-2045(17)30801-X. Epub 2017 Oct 31. No abstract available.

PMID:
29208391
12.

Aneurysms in vascular access: state of the art and future developments.

Inston N, Mistry H, Gilbert J, Kingsmore D, Raza Z, Tozzi M, Azizzadeh A, Jones R, Deane C, Wilkins J, Davidson I, Ross J, Gibbs P, Huang D, Valenti D.

J Vasc Access. 2017 Nov 17;18(6):464-472. doi: 10.5301/jva.5000828. Epub 2017 Nov 2.

PMID:
29099536
13.

Precision oncology using a clinician-directed, tailored approach to molecular profiling.

Lam M, Tran B, Beck S, Tie J, Herath D, Whittle J, Kwan EM, Fox SB, Fellowes A, Ananda S, Lipton L, Gibbs P, Rosenthal MA, Desai J.

Asia Pac J Clin Oncol. 2018 Feb;14(1):84-90. doi: 10.1111/ajco.12787. Epub 2017 Oct 30.

PMID:
29083093
14.

Circulating tumor DNA as a biomarker to guide therapy in post-operative locally advanced rectal cancer: the best option?

Tie J, Semira C, Gibbs P.

Expert Rev Mol Diagn. 2018 Jan;18(1):1-3. doi: 10.1080/14737159.2018.1386558. Epub 2017 Oct 6. No abstract available.

PMID:
28954554
15.

Understanding barriers and outcomes of unspecified (non-directed altruistic) kidney donation from both professional's and patient's perspectives: research protocol for a national multicentre mixed-methods prospective cohort study.

Gare R, Gogalniceanu P, Maple H, Burnapp L, Clarke A, Williams L, Norton S, Chilcot J, Gibbs P, Mitchell A, McCrone P, Draper H, Mamode N.

BMJ Open. 2017 Sep 21;7(9):e015971. doi: 10.1136/bmjopen-2017-015971.

16.

Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.

Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, Schmidt CM, Yip-Schneider MT, Allen PJ, Schattner M, Brand RE, Singhi AD, Petersen GM, Hong SM, Kim SC, Falconi M, Doglioni C, Weiss MJ, Ahuja N, He J, Makary MA, Maitra A, Hanash SM, Dal Molin M, Wang Y, Li L, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Goggins MG, Hruban RH, Wolfgang CL, Klein AP, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Lennon AM.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10202-10207. doi: 10.1073/pnas.1704961114. Epub 2017 Sep 5.

17.

Molecular signatures of differential responses to exercise trainings during rehabilitation.

Chen YW, Gregory C, Ye F, Harafuji N, Lott D, Lai SH, Mathur S, Scarborough M, Gibbs P, Baligand C, Vandenborne K.

Biomed Genet Genom. 2017;2(1). doi: 10.15761/BGG.1000127. Epub 2017 Apr 10.

18.

Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes.

Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ.

Eur J Cancer. 2017 Oct;84:69-80. doi: 10.1016/j.ejca.2017.07.016. Epub 2017 Aug 5. Review.

19.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.

Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators, van Hazel G, Sharma RA.

Lancet Oncol. 2017 Sep;18(9):1159-1171. doi: 10.1016/S1470-2045(17)30457-6. Epub 2017 Aug 3.

20.

Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.

Rohr UP, Herrmann P, Ilm K, Zhang H, Lohmann S, Reiser A, Muranyi A, Smith J, Burock S, Osterland M, Leith K, Singh S, Brunhoeber P, Bowermaster R, Tie J, Christie M, Wong HL, Waring P, Shanmugam K, Gibbs P, Stein U.

Ann Oncol. 2017 Aug 1;28(8):1869-1875. doi: 10.1093/annonc/mdx207.

PMID:
28460000
21.

Flaxseed- and Buckwheat-Supplemented Diets Altered Enterobacteriaceae Diversity and Prevalence in the Cecum and Feces of Obese Mice.

Pulkrabek M, Rhee Y, Gibbs P, Hall C.

J Diet Suppl. 2017 Nov 2;14(6):667-678. doi: 10.1080/19390211.2017.1305477. Epub 2017 Apr 13.

PMID:
28406725
22.

Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer.

Virdee PS, Moschandreas J, Gebski V, Love SB, Francis EA, Wasan HS, van Hazel G, Gibbs P, Sharma RA.

JMIR Res Protoc. 2017 Mar 28;6(3):e43. doi: 10.2196/resprot.7201.

23.

Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.

McNeil JJ, Woods RL, Nelson MR, Murray AM, Reid CM, Kirpach B, Storey E, Shah RC, Wolfe RS, Tonkin AM, Newman AB, Williamson JD, Lockery JE, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Trevaks RE, Orchard SG, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Grimm RH; ASPREE Investigator Group.

J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1586-1593. doi: 10.1093/gerona/glw342.

PMID:
28329340
24.

Intratumorous heterogeneity for RAS mutations in a treatment-naïve colorectal tumour.

Lunke S, Lee B, Kranz S, Gibbs P, Waring P, Christie M.

J Clin Pathol. 2017 Aug;70(8):720-723. doi: 10.1136/jclinpath-2017-204327. Epub 2017 Mar 17.

PMID:
28314739
25.

How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia?

Au L, Turner N, Wong HL, Field K, Lee B, Boadle D, Cooray P, Karikios D, Kosmider S, Lipton L, Nott L, Parente P, Tie J, Tran B, Wong R, Yip D, Shapiro J, Gibbs P.

Asia Pac J Clin Oncol. 2018 Apr;14(2):e167-e174. doi: 10.1111/ajco.12671. Epub 2017 Mar 16.

PMID:
28299879
26.

Carotenoid glycosides from cyanobacteria are teratogenic in the zebrafish (Danio rerio) embryo model.

Jaja-Chimedza A, Sanchez K, Gantar M, Gibbs P, Schmale M, Berry JP.

Chemosphere. 2017 May;174:478-489. doi: 10.1016/j.chemosphere.2017.01.145. Epub 2017 Jan 31.

27.

Engagement and outcomes for a computerised cognitive-behavioural therapy intervention for anxiety and depression in African Americans.

Jonassaint CR, Gibbs P, Belnap BH, Karp JF, Abebe KK, Rollman BL.

BJPsych Open. 2017 Jan 2;3(1):1-5. doi: 10.1192/bjpo.bp.116.003657. eCollection 2017 Jan.

28.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).

Pinter T, Klippel Z, Cesas A, Croitoru A, Decaestecker J, Gibbs P, Hotko Y, Jassem J, Kurteva G, Novotny J, O'Reilly S, Salek T, Reiner M, Morrow PK, Choi MR, Whittaker S, Blanke C.

Clin Colorectal Cancer. 2017 Jun;16(2):103-114.e3. doi: 10.1016/j.clcc.2016.08.008. Epub 2016 Sep 7.

PMID:
28038865
29.

The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study.

Lee B, Wong HL, Tacey M, Tie J, Wong R, Lee M, Nott L, Shapiro J, Jennens R, Turner N, Tran B, Ananda S, Yip D, Richardson G, Parente P, Lim L, Stefanou G, Burge M, Iddawela M, Power J, Gibbs P.

Asia Pac J Clin Oncol. 2017 Aug;13(4):314-321. doi: 10.1111/ajco.12639. Epub 2016 Nov 25.

PMID:
27885818
30.

Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma.

Tay RY, Jamnagerwalla M, Steel M, Wong HL, McKendrick JJ, Faragher I, Kosmider S, Hastie I, Desai J, Tacey M, Gibbs P, Wong R.

Clin Colorectal Cancer. 2017 Jun;16(2):e45-e54. doi: 10.1016/j.clcc.2016.09.011. Epub 2016 Oct 6.

PMID:
27825672
31.

Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.

Day D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Davis ID, Azad AA, Wong S, Rosenthal M, Gibbs P, Tran B.

Intern Med J. 2016 Nov;46(11):1291-1297. doi: 10.1111/imj.13202.

PMID:
27507629
32.

Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.

Murphy C, Turner N, Wong HL, Sinnathamby M, Tie J, Lee B, Desai J, Skinner I, Christie M, Hutchinson R, Lunke S, Waring P, Gibbs P, Tran B.

Intern Med J. 2017 Jan;47(1):88-98. doi: 10.1111/imj.13312.

PMID:
27800646
33.

Internalized Homonegativity, Sense of Belonging, and Depressive Symptoms Among Australian Gay Men.

Davidson K, McLaren S, Jenkins M, Corboy D, Gibbs PM, Molloy M.

J Homosex. 2017;64(4):450-465. doi: 10.1080/00918369.2016.1190215. Epub 2016 May 16.

PMID:
27185322
34.

Arteriovenous access ischemic steal (AVAIS) in haemodialysis: a consensus from the Charing Cross Vascular Access Masterclass 2016.

Inston N, Schanzer H, Widmer M, Deane C, Wilkins J, Davidson I, Gibbs P, Zanow J, Bourquelot P, Valenti D.

J Vasc Access. 2017 Jan 18;18(1):3-12. doi: 10.5301/jva.5000621. Epub 2016 Oct 12. Review.

PMID:
27739573
35.

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.

Cheng AL, Cornelio G, Shen L, Price T, Yang TS, Chung IJ, Dai GH, Lin JK, Sharma A, Yeh KH, Ma B, Zaatar A, Guan Z, Masood N, Srimuninnimit V, Yau T, Gibbs P, Wang X, Doval DC, Oh ST, Shim BY, Gorospe C, Wang HM, Sirachainan E, Hill A, Suh KW, Beier F, Chatterjee S, Lim R.

Clin Colorectal Cancer. 2017 Jun;16(2):e73-e88. doi: 10.1016/j.clcc.2016.08.005. Epub 2016 Sep 7.

36.

Incidence of pulmonary embolism in patients with newly diagnosed colorectal cancer.

Daniel ES, Dean AE, Lim M, Master M, Gibbs P, Faragher I.

ANZ J Surg. 2018 Apr;88(4):E228-E231. doi: 10.1111/ans.13789. Epub 2016 Oct 9.

PMID:
27723238
37.

Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.

Marriott ER, van Hazel G, Gibbs P, Hatswell AJ.

J Med Econ. 2017 Feb;20(2):193-199. doi: 10.1080/13696998.2016.1241788. Epub 2016 Oct 13.

PMID:
27676291
38.

Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer.

Millen R, Malaterre J, Cross RS, Carpinteri S, Desai J, Tran B, Darcy P, Gibbs P, Sieber O, Zeps N, Waring P, Fox S, Pereira L, Ramsay RG.

Oncoimmunology. 2016 Jun 29;5(7):e1149667. doi: 10.1080/2162402X.2016.1149667. eCollection 2016 Jul.

39.

Reply to E.C. Harrold et al and A.O. Ayoola et al.

van Hazel GA, Gibbs P.

J Clin Oncol. 2016 Dec;34(34):4194-4195. Epub 2016 Sep 30. No abstract available.

PMID:
27621391
40.

Impact of Surgical Complications Following Resection of Locally Advanced Rectal Adenocarcinoma on Adjuvant Chemotherapy Delivery and Survival Outcomes.

Jamnagerwalla M, Tay R, Steel M, Keck J, Jones I, Faragher I, Gibbs P, Wong R.

Dis Colon Rectum. 2016 Oct;59(10):916-24. doi: 10.1097/DCR.0000000000000659.

PMID:
27602922
41.

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.

Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, Kosmider S, Skinner I, Wong R, Steel M, Tran B, Desai J, Jones I, Haydon A, Hayes T, Price TJ, Strausberg RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P.

Sci Transl Med. 2016 Jul 6;8(346):346ra92. doi: 10.1126/scitranslmed.aaf6219.

42.

BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.

Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, Molloy PL, Jones IT, McLaughlin S, Gibbs P, Guinney J, Simon IM, Roth AD, Bosman FT, Tejpar S, Delorenzi M.

Clin Cancer Res. 2017 Jan 1;23(1):104-115. doi: 10.1158/1078-0432.CCR-16-0140. Epub 2016 Jun 27.

43.

26-hour Storage of a Declined Liver Before Successful Transplantation Using Ex Vivo Normothermic Perfusion.

Watson CJ, Randle LV, Kosmoliaptsis V, Gibbs P, Allison M, Butler AJ.

Ann Surg. 2017 Jan;265(1):e1-e2. doi: 10.1097/SLA.0000000000001834. No abstract available.

PMID:
27295096
44.
45.

Impact of anastomotic leak on recurrence and survival after colorectal cancer surgery: a BioGrid Australia analysis.

Sammour T, Hayes IP, Jones IT, Steel MC, Faragher I, Gibbs P.

ANZ J Surg. 2018 Jan;88(1-2):E6-E10. doi: 10.1111/ans.13648. Epub 2016 Jun 3.

PMID:
27255690
46.

Inactivation of Salmonella, Listeria monocytogenes and Enterococcus faecium NRRL B-2354 in a selection of low moisture foods.

Rachon G, Peñaloza W, Gibbs PA.

Int J Food Microbiol. 2016 Aug 16;231:16-25. doi: 10.1016/j.ijfoodmicro.2016.04.022. Epub 2016 Apr 22.

PMID:
27174678
47.

Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer.

Suraweera N, Mouradov D, Li S, Jorissen RN, Hampson D, Ghosh A, Sengupta N, Thaha M, Ahmed S, Kirwan M, Aleva F, Propper D, Feakins RM, Vulliamy T, Elwood NJ, Tian P, Ward RL, Hawkins NJ, Xu ZZ, Molloy PL, Jones IT, Croxford M, Gibbs P, Silver A, Sieber OM.

Oncotarget. 2016 Jun 14;7(24):36474-36488. doi: 10.18632/oncotarget.9015.

48.

Interaction of human biliverdin reductase with Akt/protein kinase B and phosphatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3 activity: a novel mechanism of Akt activation.

Miralem T, Lerner-Marmarosh N, Gibbs PE, Jenkins JL, Heimiller C, Maines MD.

FASEB J. 2016 Aug;30(8):2926-44. doi: 10.1096/fj.201600330RR. Epub 2016 May 10.

49.

Australian contemporary management of synchronous metastatic colorectal cancer.

Malouf P, Gibbs P, Shapiro J, Sockler J, Bell S.

ANZ J Surg. 2018 Jan;88(1-2):71-76. doi: 10.1111/ans.13619. Epub 2016 Apr 28.

PMID:
27122066
50.

Sequencing Circulating Cell-Free DNA: The Potential to Refine Precision Cancer Medicine.

Tie J, Gibbs P.

Clin Chem. 2016 Jun;62(6):796-8. doi: 10.1373/clinchem.2015.253476. Epub 2016 Apr 26. No abstract available.

Supplemental Content

Support Center